脂肪性肝炎
脂肪肝
化学
中和
非酒精性脂肪性肝炎
免疫学
生物化学
内科学
医学
疾病
抗体
非酒精性脂肪肝
作者
Xiaoli Sun,Jason S. Seidman,Peng Zhao,Ty D. Troutman,Nathanael J. Spann,Xuchu Que,Fangli Zhou,Zhongji Liao,Martina P. Pasillas,Xiaohong Yang,Jason A. Magida,Tatiana Kisseleva,David A. Brenner,Michael Downes,Ronald M. Evans,Alan R. Saltiel,Sotirios Tsimikas,Christopher K. Glass,Joseph L. Witztum
出处
期刊:Cell Metabolism
[Cell Press]
日期:2019-11-21
卷期号:31 (1): 189-206.e8
被引量:162
标识
DOI:10.1016/j.cmet.2019.10.014
摘要
Oxidized phospholipids (OxPLs), which arise due to oxidative stress, are proinflammatory and proatherogenic, but their roles in non-alcoholic steatohepatitis (NASH) are unknown. Here, we show that OxPLs accumulate in human and mouse NASH. Using a transgenic mouse that expresses a functional single-chain variable fragment of E06, a natural antibody that neutralizes OxPLs, we demonstrate the causal role of OxPLs in NASH. Targeting OxPLs in hyperlipidemic Ldlr-/- mice improved multiple aspects of NASH, including steatosis, inflammation, fibrosis, hepatocyte death, and progression to hepatocellular carcinoma. Mechanistically, we found that OxPLs promote ROS accumulation to induce mitochondrial dysfunction in hepatocytes. Neutralizing OxPLs in AMLN-diet-fed Ldlr-/- mice reduced oxidative stress, improved hepatic and adipose-tissue mitochondrial function, and fatty-acid oxidation. These results suggest targeting OxPLs may be an effective therapeutic strategy for NASH.
科研通智能强力驱动
Strongly Powered by AbleSci AI